Testing for'Bad Cholesterol' Doesn't Tell the Whole Story So why don't more doctors use it? For decades, assessing cholesterol risk has been built around a simple idea: Lower "bad" cholesterol, lower your chance of a heart attack . The test at the center of that approach measures how much low-density lipoprotein, or LDL cholesterol, is circulating in part of the blood. It has shaped everything from clinical guidelines to the widespread use of statins, medications that reduce LDL. Lowering LDL cholesterol reduces heart attacks, strokes, and early death.

Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising so far, but a finished product isn't likely coming any time soon. US-based pharmaceutical company Moderna confirmed that it has been working on the development of hantavirus vaccines in collaboration with the Vaccine Innovation Center of Korea University College of Medicine (VIC-K). This comes after an outbreak of hantavirus occurred on a Dutch cruise ship that sailed from Argentina and disembarked its passengers and crew in the Canary Islands on May 10. At least three people aboard the MV died, and several cases were reported as serious.

Jeffrey Epstein scrawled suicide note finally released: 'No fun. Surprising fate of CNN founder Ted Turner's multibillion-dollar fortune after thrice-married father-of-five died aged 87 Wall Street Titan lays out his ultimate revenge for woke NYC mayor Mamdani's'creepy weird' video Mike Vrabel'rented a boat with pregnant Dianna Russini in 2021' months before she welcomed first son Ultimate Spirit Airlines compensation guide: 'Magic words' to tell your bank for BIGGEST refund... what to do if you DIDN'T use a credit card... how to reclaim higher cost of new flights.... and'rescue' option when all else fails Once-bustling Nevada vacation resort becomes America's newest GHOST TOWN as its final hotel closes Farrah Fawcett's twisted family secrets: Siblings of her devil-horned son accused of hideous knife spree reveal dark childhood home truths Tragic Saved By The Bell star Dustin Diamond's residual pay revealed after his shock death at age 44 Rat virus'was brought onto cruise ship by birdwatcher couple who visited garbage dump to snap birds before setting off': Possible cause revealed - as Brits face eight-week quarantine Scandal as female World Cup soccer player is accused by police of raping baby-faced boy, 14, up to'three times a week' Triple Crown thrown into disarray with major announcement from Kentucky Derby winner Golden Tempo's trainer The photos that say it all! Justin Baldoni beams as he steps out with his wife for the first time since Blake Lively's humiliating lawsuit settlement The next generation of Ozempic is here. Turbo shots deliver 250% more weight loss... at record speeds. Patients are begging for them - but there's a major warning: DR SHEILA NAZARIAN Meghan Markle shares unseen photo of Prince Archie asleep on Harry's chest as a baby to celebrate his 7th birthday I sat with FedEx child killer Tanner Horner for weeks.

The Next Alzheimer's Breakthrough Will Take More Than Just Science At WIRED Health, pioneering Alzheimer's researcher John Hardy outlined the stakes--and next steps--of where treatment is headed next. Alzheimer's research is entering a new phase, as treatments that have taken decades to develop begin to reach patients . But getting those advances to people will depend on more than scientific progress alone, according to pioneering Alzheimer's researcher John Hardy . Speaking at WIRED Health in April, Hardy, chair of the Molecular Biology of Neurological Disease at University College London, said that alongside more effective drugs, better diagnosis and political will were still needed to improve treatment of Alzheimer's disease. "We've got to get better," he said.

We study high-dimensional mediation analysis in which exposures, mediators, and outcomes are all multivariate, and both exposures and mediators may be high-dimensional. We formalize this as a many (exposures)-to-many (mediators)-to-many (outcomes) (MMM) mediation analysis problem. Methodologically, MMM mediation analysis simultaneously performs variable selection for high-dimensional exposures and mediators, estimates the indirect effect matrix (i.e., the coefficient matrices linking exposure-to-mediator and mediator-to-outcome pathways), and enables prediction of multivariate outcomes. Theoretically, we show that the estimated indirect effect matrices are consistent and element-wise asymptotically normal, and we derive error bounds for the estimators. To evaluate the efficacy of the MMM mediation framework, we first investigate its finite-sample performance, including convergence properties, the behavior of the asymptotic approximations, and robustness to noise, via simulation studies. We then apply MMM mediation analysis to data from the Alzheimer's Disease Neuroimaging Initiative to study how cortical thickness of 202 brain regions may mediate the effects of 688 genome-wide significant single nucleotide polymorphisms (SNPs) (selected from approximately 1.5 million SNPs) on eleven cognitive-behavioral and diagnostic outcomes. The MMM mediation framework identifies biologically interpretable, many-to-many-to-many genetic-neural-cognitive pathways and improves downstream out-of-sample classification and prediction performance. Taken together, our results demonstrate the potential of MMM mediation analysis and highlight the value of statistical methodology for investigating complex, high-dimensional multi-layer pathways in science. The MMM package is available at https://github.com/THELabTop/MMM-Mediation.

Collecting multiple types of data on the same set of subjects is common in modern scientific applications including, genomics, metabolomics, and neuroimaging. Joint and Individual Variance Explained (JIVE) seeks a low-rank approximation of the joint variation between two or more sets of features captured on common subjects and isolates this variation from that unique to eachset of features. We develop an expectation-maximization (EM) algorithm to estimate a probabilistic model for the JIVE framework. The model extends probabilistic principal components analysis to multiple data sets. Our maximum likelihood approach simultaneously estimates joint and individual components, which can lead to greater accuracy compared to other methods. We apply ProJIVE to measures of brain morphometry and cognition in Alzheimer's disease. ProJIVE learns biologically meaningful courses of variation, and the joint morphometry and cognition subject scores are strongly related to more expensive existing biomarkers. Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Code to reproduce the analysis is available on our GitHub page.

Disease progression models infer group-level temporal trajectories of change in patients' features as a chronic degenerative condition plays out.

For these systems, a common issue is the difficulty of collecting sufficiently refined timescale data.